CK Asset’s first-half profit falls 26% amid Hong Kong property market challenges

CK Asset’s first-half profit falls 26% amid Hong Kong property market challenges

CK Asset Holdings, one of the flagship companies owned by billionaire Li Ka-shing’s family, reported weaker-than-expected first-half profit amid a challenging housing market in Hong Kong and declining rental income from its commercial properties. Profit attributable to shareholders fell 26.2 per cent to HK$6.3 billion (US$806.4 million) in the six months to June, according to…

Read More
CK Asset’s first-half profit falls 26% amid Hong Kong property market challenges

CK Asset’s first-half profit falls 26% amid Hong Kong property market challenges

CK Asset Holdings, one of the flagship companies owned by billionaire Li Ka-shing’s family, reported weaker-than-expected first-half profit amid a challenging housing market in Hong Kong and declining rental income from its commercial properties. Profit attributable to shareholders fell 26.2 per cent to HK$6.3 billion (US$806.4 million) in the six months to June, according to…

Read More
US$2.7 bn of global funds swarmed Chinese stocks in July, and the flow will be ‘stronger’

US$2.7 bn of global funds swarmed Chinese stocks in July, and the flow will be ‘stronger’

Foreign inflows to Chinese stocks will probably continue after the summer, as a regulatory push to boost shareholder returns, appealing valuations and rising expectations of interest-rate cuts in the US lure investors, according to Morgan Stanley. The rotation back to Chinese stocks was expected to be “stronger” after two consecutive months of net buying by…

Read More
Wuxi AppTec raises US$981 mn in Hong Kong offer amid growing appetite for Chinese biotech

Wuxi AppTec raises US$981 mn in Hong Kong offer amid growing appetite for Chinese biotech

Wuxi AppTec, Asia’s largest provider of contract pharmaceutical research, has raised HK$7.70 billion (US$981 million) through a sale of additional shares in Hong Kong as it rides the wave of bullish appetite for Chinese biotechnology shares. The Shanghai-based company sold 73.8 million new shares to institutional investors at HK$104.27 each, a 6.9 per cent discount…

Read More
Wuxi AppTec raises US$981 mn in Hong Kong offer amid growing appetite for Chinese biotech

Wuxi AppTec raises US$981 mn in Hong Kong offer amid growing appetite for Chinese biotech

Wuxi AppTec, Asia’s largest provider of contract pharmaceutical research, has raised HK$7.70 billion (US$981 million) through a sale of additional shares in Hong Kong as it rides the wave of bullish appetite for Chinese biotechnology shares. The Shanghai-based company sold 73.8 million new shares to institutional investors at HK$104.27 each, a 6.9 per cent discount…

Read More